Creative Biolabs Expands AI-Driven Antibody Discovery Portfolio

Integrated protein modeling, motion simulation, and AI-driven HTS screening help research teams prioritize preclinical antibody candidates and evaluate developability early.
New York, USA - August 6, 2026 - As biopharmaceutical research targets complex disease mechanisms-such as multi-pass membrane proteins, transient protein-protein interactions (PPIs), and cryptic epitopes-traditional empirical screening often faces high attrition rates and extended timelines. Early-stage decisions frequently rely on limited structural data, increasing the risk of downstream developability failures.

Image: https://www.globalnewslines.com/uploads/2026/05/3a75e3371c2852e442807ca390c097e0.jpg

To address these preclinical bottlenecks, Creative Biolabs has expanded its computational biology capabilities into a unified AI-driven antibody discovery framework. By integrating primary sequence analysis, 3D structural prediction, conformational dynamics, and in silico developability profiling, the platform provides biopharma researchers with actionable hypotheses to prioritize lead candidates before committing to resource-intensive laboratory assays.

AI-Driven Protein Modeling for Structure-Based Discovery

At the foundation of the expanded portfolio is the AI-driven protein modeling service [https://ai.creative-biolabs.com/ai-protein-modeling-service.htm], which translates primary amino acid sequences into predicted three-dimensional coordinates.

Built upon deep-learning architectures-including graph neural networks and attention-based models inspired by AlphaFold-the service generates structural models for target antigens, antibodies, and engineered constructs. Rather than replacing X-ray crystallography or cryo-EM, computational modeling serves as a rapid prioritization layer to:

Map Functional Interfaces: Identify putative epitope-paratope interactions and contact residues at atomic resolution.

Support Structure-Guided Design: Enable rational mutagenesis and affinity maturation strategies without waiting for experimental structure determination.

Model Complex Targets: Generate working structural hypotheses for challenging antigens where crystallization is technically difficult.

Protein Motion Simulation for Dynamic Interaction Analysis

Because biological recognition occurs in a dynamic physiological environment, static crystal structures or consensus models can overlook critical functional states. Creative Biolabs complements static modeling with its AI-driven protein motion simulation service [https://ai.creative-biolabs.com/ai-protein-motion-simulation-service.htm].

Using machine learning-enhanced force fields and coarse-grained fragmentation methods, the platform simulates conformational trajectories over biologically relevant timescales. This dynamic sampling allows researchers to:

Uncover Transient States: Identify transiently open binding pockets, cryptic epitopes, and allosteric sites that remain hidden in static conformations.

Evaluate Conformational Flexibility: Assess how CDR loop flexibility influences binding kinetics and target specificity.

Compress Computational Sampling: Reduce molecular dynamics calculation times from weeks to days, enabling comparative dynamic screening across lead panels.

AI-Driven HTS Smart Screening for Candidate Prioritization

To bridge atomic-level modeling with large-scale candidate selection, Creative Biolabs has deployed its AI-driven HTS smart screening service. Designed to identify sequence liabilities early in the discovery funnel, the service evaluates biophysical and biochemical profiles across antibody libraries.

Trained on curated datasets of clinical and approved biotherapeutics, the platform assesses key developability parameters in silico , including:

Thermal Stability & Aggregation Propensity: Flagging hydrophobic patches and surface motifs associated with colloidal instability.

Sequence Liabilities: Identifying potential deamidation, isomerization, and oxidation motifs within CDRs.

Physicochemical Profiling: Calculating expected isoelectric point ($mathrm{pI}$), surface hydrophobicity, and potential immunogenicity risks.

Candidates are benchmarked against reference therapeutic antibodies, providing teams with ranked candidate lists and specific engineering recommendations to mitigate downstream manufacturing risks.

Upcoming Webinar & Preclinical Consultation

To demonstrate how integrated computational and experimental workflows are applied in active drug discovery programs, Creative Biolabs will host a live educational webinar titled "Novel Platforms for Preclinical Antibody Discovery" on August 11, 2026, at 11:00 AM EDT. Featuring Dr. Ivelin Georgiev, the session will explore practical case studies on AI-guided epitope profiling, developability triage, and bench-to-computational integration. Biopharmaceutical professionals interested in attending can register online today to reserve a virtual seat [https://ai.creative-biolabs.com/novel-platforms-for-preclinical-antibody-discovery.htm], or contact the Creative Biolabs computational biology team directly to request a preliminary developability assessment and a customized project proposal.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=creative-biolabs-expands-aidriven-antibody-discovery-portfolio]
Phone: 1-631-830-6441
Country: United States
Website: https://ai.creative-biolabs.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.